MedTrace Logo

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

NCT00585416 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2015-10-02

No results posted yet for this study

Summary

The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with metastatic hormone refractory prostate cancer as measured by changes in PSA.

Conditions

Interventions

DRUG

CGC-11047

CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)

Sponsors & Collaborators

  • Progen Pharmaceuticals

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-11-30
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00585416 on ClinicalTrials.gov